Search

Displaying results 81 - 90 of 238 in total
  1. Drug

    Imelasomeran

    go.drugbank.com/drugs/DB17090
    ApprovedInvestigational

    [L45320] It encodes for the viral spike protein of the Omicron BA.1 variant of SARS-CoV-2, a particularly infectious variant of concern first documented in 2021.[L43922]

  2. Drug

    Remdesivir

    go.drugbank.com/drugs/DB14761
    ApprovedInvestigational

    [A191427, A198810] Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV,[A222398] and has been investigated in multiple COVID-19 clinical … Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia

    Categories: SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor
  3. Drug

    Racementhol

    go.drugbank.com/drugs/DB14123
    ApprovedInvestigational

    Mixtures: Nan San MUSFLEX External Analgesic, Nan San MUSFLEX External AnalgesicProducts: SANA SANA Menthol External Analgesic, Nan San EASY FLEX Pain Relieving
  4. Drug

    Tozinameran

    go.drugbank.com/drugs/DB15696
    ApprovedInvestigational

    It is designed to induce immunity against SARS-CoV-2, the virus responsible for causing COVID-19. … [A225386] Comirnaty was granted a EUA in the UK on December 2, 2020,[L26676] and in Canada on December 9, 2020[L26671] for active immunization against SARS-CoV-2.

  5. Drug

    Andusomeran

    go.drugbank.com/drugs/DB18227
    ApprovedInvestigational

    Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season. It is similar to previous mRNA vaccines developed by Moderna (e.g. elasomeran, imelasomeran), but is designed to be effective against the Omicron XBB.1...

  6. Drug

    Imdevimab

    go.drugbank.com/drugs/DB15940
    ApprovedInvestigational

    [A224429] These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape.

  7. Drug

    Casirivimab

    go.drugbank.com/drugs/DB15941
    ApprovedInvestigational

    [A224429] These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape.

  8. Drug

    Famtozinameran

    go.drugbank.com/drugs/DB17088
    ApprovedInvestigational

    The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. … [L43917] Famtozinameran is an mRNA vaccine encoding the S glycoprotein of SARS-CoV-2 Omicron variant lineages BA.4 and BA.5.

  9. Drug

    Ensitrelvir

    go.drugbank.com/drugs/DB18834
    ApprovedInvestigational

    Ensitrelvir is an oral small-molecule antiviral that inhibits the SARS-CoV-2 main protease (Mpro, also known as 3CLpro), an enzyme the virus needs to replicate. … [A286912, L63347] Ensitrelvir was first approved in Japan, receiving emergency regulatory approval in November 2022 and standard approval on 5 March 2024 for the treatment of SARS-CoV-2 infection.

  10. Drug

    Nirmatrelvir

    go.drugbank.com/drugs/DB16691
    ApprovedInvestigational

    [L33354] 3CL<sup>PRO</sup> is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. … [A234224,A234229,A234234] In 2020, Pfizer was investigating another potential treatment for SARS-CoV-2, [PF-07304814].